23:41 , Dec 12, 2017 |  BC Extra  |  Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
23:42 , Sep 14, 2017 |  BC Extra  |  Company News

Management tracks: SymCel, Taro, Akcea

SymCel Sverige AB (Spanga, Sweden) named Jesper Ericsson CEO. He was director of marketing and sales at BioLamina AB (Stockholm, Sweden). SymCel offers a cell-based assay for real-time monitoring of cell metabolism. Prescription and OTC...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Financial News

Eyevensys financial update

Eyevensys S.A.S. , Paris, France   Business: Ophthalmic   Date announced: 2016-09-15   Note: Eyevensys raised an undisclosed amount in an extension of a series A round, bringing the total raised in the round to...
08:00 , Dec 3, 2015 |  BC Innovations  |  Product R&D

Eyeing fewer needles

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Financial News

Eyevensys completes venture financing

Eyevensys S.A.S. , Paris, France   Business: Ophthalmic   Date completed: 2015-10-09   Type: Venture financing   Raised: EUR7.5 million ($8.5 million)   Investors: Boehringer Ingelheim Venture Fund; Bpifrance ; CapDecisif; Inserm Transfert  ...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Financial News

Eyevensys completes venture financing

Eyevensys S.A.S. , Paris, France   Business: Ophthalmic   Date completed: 4/11/13   Type: Venture financing   Raised: Not disclosed   Investors: Boehringer Ingelheim Venture Fund  ...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Eyevensys board of directors update

Eyevensys S.A.S. , Paris, France   Business: Ophthalmic   Appointed: Michel Pairet, head of non-clinical R&D at Boehringer Ingelheim GmbH  ...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Eyevensys management update

Eyevensys S.A.S. , Paris, France   Business: Ophthalmic   Hired: Ivan Cohen-Tanugi as CEO, formerly VP and general manager of the biologics and specialty unit at Teva Pharmaceutical Industries Ltd.  ...
08:00 , Feb 13, 2012 |  BioCentury  |  Finance

Ventech reinvention

Ventech reinvention Ventech's life science specialists have landed at INSERM after the French VC decided to focus solely on IT. The life sciences team - General Partner Mounia Chaoui and Principal Laurent Assaraf - have...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Financial News

Eyevensys completes venture financing

Eyevensys S.A.S. , Paris, France   Business: Ophthalmic   Date completed: 1/23/12   Type: Venture financing   Raised: €950,000 ($1.2 million)   Investors: InnoBio Fund; Inserm Transfert Initiative  ...